Prexton Therapeutics

Prexton Therapeutics is the first spin-off company from EPP Fund. The company is developing programs in Parkinson’s disease focused on targeting the metabotropic glutamate receptors mGluR3 and mGluR4. Prexton Therapeutics is based in Geneva, Switzerland.

Team Member
more about
Jasper Bos
Latest News Entry
Prexton Therapeutics Series B financing round raises €29 million ($31M) to advance its novel Parkinson’s therapeutic

Forbion & Seroba co-led funding, forming international consortium of Merck Ventures, Ysios and Sunstone
Funding to finance two Phase II trials in Parkinson’s disease

Geneva, Switzerland and Amsterdam, The Netherlands, February 7, 2017 - Prexton Therapeutics (Prexton), a biopharmaceutical company developing novel therapeutic compounds for the treatment of Central Nervous System (CNS) conditions, today announces the closing of a Series B financing round of €29 million ($31M).

all portfolio news